This route however appears to be largely ignored and probably will continue to be ignored, since the strategy so far has been to simply create agonists which are structurally designed to be resistant to DPP-4 (In fact, most modifications to extend the half-life of GLP1R/GIPR/GR agonists so far, do so by making the drugs resistant to DPP-4 )
Kunnumakkara AB, Banik K, Bordoloi D, Harsha C, Sailo BL, Padmavathi G, et al
Discovery of the Ergothioneine Transporter
Researchers tracking peptides for depression and anxiety should be aware that mood changes and fatigue can overlap with metabolic adjustments
Providers in high cost-of-living areas might charge more than those in lower-cost regions
While competition exists, its superior clinical profile and aggressive expansion into lower-cost vials and Medicare coverage provide a "clear lane" for rapid market share capture